Hubungan Kadar Procalcitonindengan Demam Neutropenia pada Leukemia Limfoblastik Akut Anak
Sari
Latar belakang. Kejadian infeksi bakteri pada leukemia limfoblastik akut (LLA) lebih tinggi pada demam neutropenia (DN).
Procalcitonin(PCT) memiliki sensitivitas dan spesifisitas yang lebih baik dibanding dengan C-reactive protein(CRP). Hal ini
masih menjadi perdebatan, pada penelitian sebelumnya dinyatakan bahwa CRP lebih baik dibanding dengan PCT.
Tujuan. Menentukan hubungan PCT dengan DN pada LLA anak dengan mengikutsertakan CRP.
Metode. Penelitian potong lintang pada 78 subjek usia 0-13 tahun dengan DN dan demam tanpa neutropenia (DTN) yang
memenuhi kriteria inklusi dilakukan pemeriksaan PCT serum. Pemilihan subjek secara consecutive sampling. Variabel dengan nilai
p<0,25 pada analisis bivariat dilanjutkan analisis multivariat dengan rasio Odds (RO) dan interval kepercayaan (IK) 95%.
Hasil.Di antara 78 pasien LLA didapatkan 27 DN dan 51 DTN. Hubungan kadar PCT dan CRP serum dengan DN berturut-turut
RO 3,618 (IK95%: 1,227–10,665) dan RO 3,676 (IK95%: 1,22–11,028). Procalcitonin dan CRP memperlihatkan diskriminasi
yang baik dengan AUC 0,752 (IK 95%: 0,639–0,866) serta kalibrasi yang kuat (p=0,692).
Kesimpulan. Procalcitoninserum berhubungan dengan DN pada LLA anak yang meningkat hubungannya dengan mengikutsertakan
CRP
Kata Kunci
Teks Lengkap:
PDFReferensi
Lanzkowsky P. Manual of pediatric hematology and
oncology. Edisi kelima. New York: Churchill Livingtone;
h.518-49.
Pernomo B, Ugrasena I. penyunting. Buku ajar
hematoonkologi anak 3. Jakarta: IDAI; 2010.h.234-45.
Mulyani, Aryani D, Andalusia R. Evaluasi penggunaan
antibiotik pada pasien pediatri leukemia limfoblastik
akut dengan febrile neutropenia selama pemberian
kemoterapi di Rumah Sakit Kanker Dharmais Jakarta.
Media Farmasi 2014;11:98-107.
Anna F, Luaces C, Garcia J. Procalcitonin in pediatric
emergency departements for the early diagnosis of
invasive bacterial infections in febrile infants: results of
a multicenter study and utility of a rapid qualitative test
for this marker. Pediatr Infect Dis J 2003;22:895-903.
Van D, Witte M, Kremer L, Offringa M, Scholten R,
Caron H. Efficacy of oral prophylatic antibiotics in
neutropenic afebrile oncology patients: a systematic
review of randomised controlled trials. Eur J Cancer
;41:1372-82.
Stefanus G, Novie H, Max F, Rampenga T. Febrile
neutropenia in childhood leukemia: Manado experience
–2006. Pediatr Indones 2009;49:372-8.
Robinson JO, Lamoth F, Bally F, Knaup M, Calandra
T, Marchetti O. Monitoring procalcitonin in febrile
neutropenia: What is its utility for initial diagnosis of
infection and reassesment in persistent fever. Plos One
;6:1-9.
Meidani M, Khorvash F, Abolghasemi H, Jamali B.
Procalcitonin and quantitative C-reactive protein role
in the early diagnosis of sepsis in patients with febrile
neutropenia. SAJC 2013;2:216-9.
Kitanovski L, Jazbee J, Hojker S, Dergane M. Diagnostic
accuracy of lipopolysaccharide-binding protein for
predicting bacteremia/clinical sepsis in children with
febrile neutropenia: comparison with interleukin-6,
procalcitonin, and C-reactive protein. Support Care
Cancer 2014;22:269-77.
Urbonas V, Eidukaite A, Tamuliene I. The predictive value of soluble biomarkers (CD14 subtype, interleukin-2
receptor, human leucocyte antigen-G) and procalcitonin
in the detection of bacteremia and sepsis in pediatric
oncology patients with chemotherapy-induced febrile
neutropenia. Cytokine 2013;62:34-7.
Hadir M, Ibrahim A, Hala M, Meer H, Al-Mobarak
M. Fever and granulocytopenia in children with acute
lymphoblastic leukemia under induction therapy. Saudi
J Med 2001;22:423-7.
Shomali W, Hachem R, Chaftari A-M, Jiang Y, Bahu
R, Jabbour J. Can procalcitonin distinguish infectious
fever from tumor-related fever in non-neutropenis cancer
patients? Cancer 2012;1:5823-9.
Barraf L. Practice guidelines for the management of
infant and children 0-36 months of age with fever
without source. Agency for healthcare policy and
research. Ann Emerg Med 1993;22:1198-210.
Santolaya M, Alvarez A, Becker A, Cofre J, Enri’quez
N, O’Ryan M. Prospective, multicenter evaluation of
risk factors associated with invasice bacterial infection
in children with cancer, neutropenia, ad fever. J Clin
Oncol 2001;19:3415-21.
Boysen AK, Jensen BR, Paulsen L, Jensen P. Procalcitonin
as a marker of infection in febrile neutropenia: a
systematic review. Modern Chemother 2013;2:8-14.
Chaudhury A, Sumant S, Jayaprada R, Kalawat U.
Procalcitonin in sepsis and bacterial infections. J Clin
Sci Res 2013;2:216-24.
Kim DY, Lee Y-S, Ahn S, Chun YH, Lim KS. The
usefulness of procalcitonin and C-reactive protein as early
diagnostic markers of bacteremia in cancer patients with
febrile neutropenia. Cancer Res Treat 2011;43:176-80.
Erten N, Genc S, Besisik SK, Saka B, Karan MA,
Tascioglu C. The predictive and diagnostic values of
procalcitonin and C-reactive protein for clinical outcome
in febrile neutropenic. J Chin Med Assoc 2004;67:217-21.
Dale D, Cottle T, Fier C. Severe chronic neutropenia :
treatment and follow up of patients in the severe chronic
neutropenia international registry. Am J Hematol
;72:82-93.
Hamidah A, Rizal A, Nordiah A. Piperacillin-tazobactam
plus amikasin as an initial empirical therapy of febrile
neutropenia in paediatric cancer patients. Singapure Med
J 2008;49:26-30.
Dilek G, Kamer M, Hilal C, Hatice A, Deniz A, Olgun
N. Febrile neutropenic episodes in children with
lymphoma and malignant solid tumors. J Pediatr Infect
;4:1-8.
Long SS, Pickering LK, Prober CG. The systemic
inflammatory respons syndrome (SIRS), sepsis, and
septic shock. Dalam: Gusman J, penyunting. Principles
and practice of pediatric infectious diseases. Edisi
keempat. Philadelphia: Saunders; 2012.h. 97-9.
Goldstein B, Giroir B, Randolp A. International pediatric
sepsis consensus conference: definition for sepss and
organ dysfunction in pediatrics. Pediatr Crit Care Med.
;6:2-8.
Hatzistilianou M, Rekleity A, Athanassiadou F,
Lutiis MAD, Conti P, Catriu D. Serial procalcitonin
responses in infection of children with secondary
immunodeficiency. Clin Invest Med 2007;30:E75-85.
Shehabi Y, Seppelt I. Pro/con debate: is procalcitonin
useful for guiding antibiotic decison making in critically
ill patients? Crit Care 2008;2:211-6.
Mendez AVA, Sapolnik R, Mendonca N. New guidelines
for the clinical management of febrile neutropenia
and sepsis in pediatric oncology patiens. J Pediatr
;83:554-63.
Lodahl D, Schroder H. Procalcitonin adds to diagnosis,but does not reduce initial antibiotics in febrile
neutropenic children. Danish Medical Bulletin
;58:1-5.
Albarran MM, Molina JP, Castorena SG, Zubieta FS.
Procalcitonin and C-reaktive protein serum levels as
a markers of infection in a pediatric population with
febrile neutropenia and cancer. J Pediatr Hematol Oncol
;26:412-25.
Kohli V, Singhi S, Sharma P, Ganguly N. Value of
serum C-reactive protein concentration in febrile
children without apparent focus. Ann Trop Paediatr
;13:373-8.
Giammarellou H, Giamarellos-Bourboulis EJ, Repoussis
P, Galani L, Anagnostopoulos N, Greka P, dkk. Potential
use of procalcitonin as a diagnostic criterion in febrile
neutropenia: experience from a multicentre study. Clin
Microbiol Infect 2004;10:628-33.
Becker K, Snider R, Nylen E. Procalcitonin assay in
systemic inflammation, infection, and sepsis: clinical
utility and limitations. Crit Care Med 2008;36:941-52.
DOI: http://dx.doi.org/10.14238/sp17.4.2015.267-72
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc-sa4.footer##
Email: editorial [at] saripediatri.org
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.